1.
|
Phase: Phase IV Type: Natural history/Epidemiology, Supportive care Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2007-005844-26, NCT00903188
|
|
2.
|
Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CRAD001JIL05, NCT01231659
|
|
3.
|
Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CRAD001LDE36T, 2010-021370-11, NCT01266837
|
|
4.
|
Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CRAD001LDE43, 2011-003416-23, NCT01514448
|
|
5.
|
Phase: Phase IV Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CRAD001K24133E1, NCT01595009
|
|
6.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CRAD001N2301, 2008-000498-40, NCT00790036
|
|
7.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 to 65 Sponsor: Other Protocol IDs: 2007.489/32, NCT00799188
|
|
8.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CRAD001J2301, 2008-006556-21, NCT00876395
|
|
9.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: SWOG-S0931, S0931, NCT01120249
|
|
10.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: CALGB-90802, CALGB-90802, NCT01198158
|
|
11.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CRAD001RDE35T, NCT01248403
|
|
12.
|
Phase: Phase III Type: Supportive care Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: Esperanz-002, NCT01265810
|
|
13.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CRAD001T2302, 2011-002887-26, NCT01524783
|
|
14.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Health services research, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CRAD001JDE49, NCT01626222
|
|
15.
|
Phase: Phase III Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: NCI Protocol IDs: SWOG-S1207, S1207, NCT01674140
|
|
16.
|
Phase: Phase III Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CA209-025, 2011-005132-26, NCT01668784
|
|
17.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 20 to 75 Sponsor: Other Protocol IDs: CRAD001C2453, NCT00390195
|
|
18.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000544786, MAYO-LS0689, MAYO-07-000710, LS0689, NCT00474929
|
|
19.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 06-352, NCT00516165
|
|
20.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 4P-09-4, AVF3955s, CRAD001CUS2468, NCT00574769
|
|
21.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: MC0886, NCI-2009-00934, 08-004746, CLBH589BUS17T, NCT00918333
|
|
22.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 040803, P30CA072720, CDR0000648116, 0220090058, CRAD001C2448;, CINJ-040803, NOVARTIS-CINJ-040803, NCT00934895
|
|
23.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CRAD001JDE15T, NCT00930475
|
|
24.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: MC088C, NCI-2009-00935, 08-008775, NCT00935792
|
|
25.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2009-0100, NCT00968253
|